8-K filed August 12, 2021, 7:59 PM ET ticker TARS CIK 0001819790

leadership confidence high sentiment positive materiality 0.35

Tarsus Pharmaceuticals appoints Rosemary A. Crane to Board; creates Science and Technology Committee

Tarsus Pharmaceuticals, Inc.

Crane appointed to Board effective Aug 11, 2021; will chair Audit and new Science and Technology Committees.
Jason Tester resigned from Board and Audit Committee on Aug 10, 2021; no disagreement with Company.
Wendy Yarno appointed Chair of Compensation Committee; Andrew Goldberg moved to Science and Technology Committee.
Crane receives initial option for 20,000 shares under non-employee director compensation policy.
Crane brings 30+ years pharma experience, including former CEO of MELA Sciences and Epocrates, senior roles at J&J and Bristol Myers Squibb.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Rosemary A. Crane

Chair of the Science and Technology Committee

TARS · Tarsus Pharmaceuticals, Inc.

Effective: 2021-08-11
Filed: August 12, 2021, 7:59 PM ET

The Board appointed Ms. Crane to serve as Chair of the Science and Technology Committee

Appointed

Rosemary A. Crane

Director

TARS · Tarsus Pharmaceuticals, Inc.

Effective: 2021-08-11
Filed: August 12, 2021, 7:59 PM ET

appointed Rosemary A. Crane to the Board, effective immediately.

Appointed

Rosemary A. Crane

Chair of the Audit Committee

TARS · Tarsus Pharmaceuticals, Inc.

Effective: 2021-08-11
Filed: August 12, 2021, 7:59 PM ET

the Board appointed Ms. Crane to serve as Chair of the Audit Committee of the Board.

Departed

Jason Tester

Director

TARS · Tarsus Pharmaceuticals, Inc.

Effective: 2021-08-10
Successor: Rosemary A. Crane
Filed: August 12, 2021, 7:59 PM ET

Jason Tester, a member of the Company's Board and Chair of the Audit Committee of the Board, resigned from the Board and the Audit Committee of the Board

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Rosemary A. Crane was appointed as Chair of the Science and Technology Committee at Tarsus Pharmaceuticals, Inc..

Action: appointed
Role: Chair of the Science and Technology Committee

Exact text from the filing

The Board appointed Ms. Crane to serve as Chair of the Science and Technology Committee

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Rosemary A. Crane was appointed as Director at Tarsus Pharmaceuticals, Inc..

Action: appointed
Role: Director

Exact text from the filing

appointed Rosemary A. Crane to the Board, effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Rosemary A. Crane was appointed as Chair of the Audit Committee at Tarsus Pharmaceuticals, Inc..

Action: appointed
Role: Chair of the Audit Committee

Exact text from the filing

the Board appointed Ms. Crane to serve as Chair of the Audit Committee of the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Jason Tester resigned as Director at Tarsus Pharmaceuticals, Inc..

Action: resigned
Role: Director

Exact text from the filing

Jason Tester, a member of the Company's Board and Chair of the Audit Committee of the Board, resigned from the Board and the Audit Committee of the Board

View on SEC.gov

Tarsus Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-21-244642

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.